| Tumor Characteristics | IRAQI Patients | BRITISH Patients | Chi square Test |
|---|---|---|---|
| - | N= 331 (%) | N= 242 (%) | P value |
| MEAN AGE (SD) | 42.1 (6.01) | 43.3 (5.11) | - |
| HISTOLOGIC TYPE | - | - | 0.6182 |
| IDC (NOS) | 250 (85.0) | 187 (83.5) | |
| ILC | 25 (8.5) | 16 (7.1) | |
| Mixed | 7 (2.4) | 7 (3.1) | |
| Others | 12 (4.1) | 14 (6.2) | |
| TUMOR SIZE | - | - | < .00001 |
| T1 | 62 (19.9) | 115 (52.3) | |
| T2 | 175 (56.3) | 91 (41.7) | |
| T3 | 58 (18.6) | 11 (5.0 | |
| T4 | 16 (5.1) | 3 (0.9) | |
| LYMPH NODE | - | - | < .00001 |
| N0 | 90 (29.7) | 144 (67.9) | |
| N1 | 93 (30.6) | 60 (28.3) | |
| N2 | 73 (24.1) | 6 (2.8) | |
| N3 | 47 (15.5) | 3 (0.9) | |
| HISTOLOGIC GRADE | - | - | 0 .00003 |
| I | 18 (7.2) | 28 (12.3) | |
| II | 156 (63) | 95 (42) | |
| III | 74 (29.8) | 103 (45.6) | |
| CLINICAL STAGE | Queen's : 128 cases | < .00001 | |
| I | 33 (12.2) | 47 (43.1) | |
| II | 119 (44.2) | 56 (51.4) | |
| III | 95 (35.3) | 5 (4.6) | |
| IV | 22 (8.2) | 2 (0.9) | |
| ESTRORECEPTOR (ER) | - | - | < .00001 |
| Positive | 189 (65.2) | 192 (83.5) | |
| Negative | 101 (34.8) | 38 (16.5) | |
| PROGESTERONE RECEPTOR | - | - | 0.0001 |
| Positive | 182 (62.5) | 88 (82.2) | |
| Negative | 109 (37.5) | 19 (17.8) | |
| HER2 STATUS | - | - | 0.1121 |
| Positive | 86 (30.3) | 49 (23.7) | |
| Negative | 198 (69.7) | 157 (76.2) | |
| BREAST CANCER SUBTYPES | - | - | 0 .0016 |
| Luminal A (E+/P+/HER2-) | 120 (49.8) | 58 (74.3) | |
| Luminal B (E+/P+/HER2+ ) | 40 (16.6) | 12 (14.1) | |
| HER2 Enriched (E-/P-/HER2+) | 29 (12) | 4 (3.8) | |
| Triple Negative (E-/P-/HER2-) | 52 (21.6) | 6 (7.7) |